Cargando…
Real life results in using 5-ASA for maintaining mild to moderate UC patients in Japan, a multi-center study, OPTIMUM Study
BACKGROUND: Efficacy of maintenance therapy in ulcerative colitis (UC) in the remission stage has been reported to depend on release profile or dosing regimen of oral 5-aminosalicylic acid (5-ASA) products used. Aim of this study is to investigate real life results in using oral 5-ASA products for m...
Autores principales: | Nagahori, Masakazu, Kochi, Shuji, Hanai, Hiroyuki, Yamamoto, Takayuki, Nakamura, Shiro, Omuro, Soji, Watanabe, Mamoru, Hibi, Toshifumi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5385245/ https://www.ncbi.nlm.nih.gov/pubmed/28390410 http://dx.doi.org/10.1186/s12876-017-0604-y |
Ejemplares similares
-
Efficacy and safety of a new vedolizumab subcutaneous formulation in Japanese patients with moderately to severely active ulcerative colitis
por: Kobayashi, Taku, et al.
Publicado: (2021) -
Evidence-based clinical practice guidelines for Crohn’s disease, integrated with formal consensus of experts in Japan
por: Ueno, Fumiaki, et al.
Publicado: (2012) -
Modelling the benefits of an optimised treatment strategy for 5-ASA in mild-to-moderate ulcerative colitis
por: Louis, Edouard, et al.
Publicado: (2022) -
Predicting outcomes to optimize disease management in inflammatory bowel disease in Japan: their differences and similarities to Western countries
por: Kobayashi, Taku, et al.
Publicado: (2018) -
Four-year maintenance treatment with adalimumab in Japanese patients with moderately to severely active ulcerative colitis
por: Suzuki, Yasuo, et al.
Publicado: (2017)